What Redormin Treats: Main Uses and Benefits

The therapeutic role of Redormin (Remifentanil) involves providing supportive relief for symptoms associated with acute or episodic changes. The medication is utilized in areas where short-term symptom management is appropriate, typically within clinical settings.

Quick Fact: Relief for Acute Surgical Pain

The medication is relevant in clinical contexts that involve varying symptom patterns.

This medication is used for managing conditions characterized by periods of heightened symptoms, and is relevant in situations involving analgesia during the induction and maintenance of general anesthesia, as well as providing symptomatic relief in mechanically ventilated patients in the Intensive Care Unit (ICU).

It is commonly used to help with symptom clusters that may become intense or disruptive, such as severe acute pain, physiological stress responses during surgery, and agitation or restlessness in the ICU. The medication supports the patient during difficult episodes by easing distress, which may assist with maintaining functional stability during symptomatic periods.

“It is commonly used to help with short-term symptom stabilization, providing support that helps ease the overall symptom burden.”

Regulatory References

1. Summary of Product Characteristics from a National Regulatory Authority

Who Can and Cannot Use Redormin?

The eligibility for Redormin (Remifentanil) is strictly defined by regulatory authorities for use in acute medical settings. The official labeling specifies approved populations, absolute prohibitions, and conditions requiring caution.

Populations and Eligibility Status

Population Group	Regulatory Eligibility Status
Adults (18+)	Approved for general anesthesia and ICU sedation.
Pediatric (1–12 years)	Approved for general anesthesia only.
Neonates (1 day – 6 months)	Approved for maintenance of general anesthesia in specific surgical contexts.
Older Adults (>65 years)	Conditional Use: Require a lower initial dose due to increased sensitivity.

Absolute Prohibitions (Contraindications)

Redormin is absolutely contraindicated in the following patient groups, as stated in official regulatory documents:

• Patients with a known hypersensitivity to remifentanil or other fentanyl analogues.
• Any administration via the epidural or intrathecal routes.

Use Restrictions

Certain physiological states and conditions require restriction or special consideration:

• Pregnancy/Lactation: Use during pregnancy is generally not recommended unless clearly necessary; it is not recommended for breastfeeding mothers.
• Pediatric ICU Sedation: Use for managing sedation in mechanically ventilated children in the ICU (under 12 years) is not established and is therefore not recommended.
• Organ Function: No specific dose adjustment is required for patients with renal or hepatic impairment, as the drug's metabolism is independent of liver and kidney function.

Redormin, which contains extracts from Valerian root and Hops, can interact with other substances, primarily those that also affect the central nervous system (CNS).

Potential Pharmacodynamic Interactions

The most significant known interactions are those that may enhance the sedative or depressant effects on the CNS. Concurrent use with these substances should be avoided or closely monitored by a healthcare professional.

Category	Examples of Affected Substances	Potential Effect
CNS Depressants	Alcohol, Benzodiazepines (e.g., diazepam, lorazepam), Barbiturates, Opioid pain medications, and some Antihistamines	Increased drowsiness, sedation, or risk of breathing problems.
Other Sedative Herbs	Catnip, Chamomile, Kava, Lemon Balm, Melatonin	Potential for additive sedative effects.

Impact on Medication Metabolism

While Valerian and Hops extracts are generally considered to have a low risk of clinically relevant interactions, they may influence liver enzymes, specifically the cytochrome P450 (CYP) enzymes, which are responsible for breaking down many medications. This is an area where specific studies have yielded mixed results, but caution is warranted.

• Enzyme Modulation: In theory, changes in the activity of enzymes like CYP3A4, CYP2D6, or CYP1A2 could potentially alter the concentration of co-administered drugs in the body, which might increase the risk of side effects or reduce the drug's effectiveness.
• Prior to Surgery: Because of the potential for increased sedation, patients should inform their surgeon and stop taking Redormin at least two weeks before any scheduled surgical procedure requiring anesthesia.

How Redormin Works: Mechanism of Action

Redormin, a combination of standardized Valerian and Hops extracts, influences central nervous system (CNS) function through a multi-target mechanism engaging both acute inhibitory signaling and pathways that regulate circadian timing.

Enhancement of Inhibitory GABA Signaling

Valerian's active components function as Positive Allosteric Modulators (PAMs) of the GABAA receptor complex. By binding to allosteric sites, these components potentiate the effect of endogenous GABA, the CNS's primary inhibitory neurotransmitter. This action increases chloride ion flux, resulting in neuronal hyperpolarization and a reduction in overall neuronal excitability. This change in excitability is associated with decreased sleep latency.

Modulation of Sleep-Wake Regulation

Hops and valerian components interact with systems that govern sleep timing. Components are understood to modulate melatonin receptors ( MT1, MT2) and pathways regulating adenosine and serotonin ( 5-HT5A) signaling. This modulation affects the homeostatic pressure and timing of the sleep-wake cycle, influencing the structure and duration of the sleep cycle. The combined GABAergic inhibition and pathway modulation affects both acute neural activity and sleep-wake transition.

How Redormin is Used: Official Administration Guidelines

Redormin (Remifentanil Hydrochloride) is a medicine intended for use exclusively in controlled clinical settings, such as operating theatres and intensive care units. Its administration and dosage are strictly defined, reflecting its rapid onset and ultra-short duration of action.

---

Administration Protocol

Feature	Official Instruction Summary
Administration Route	Intravenous (IV) use only; administration by epidural or intrathecal routes is strictly prohibited.
Dosing Schedule	Administered as a continuous, titratable IV infusion to maintain sustained analgesia. Supplemental slow IV bolus injections may be given during anesthesia maintenance, but bolus dosing is not recommended for immediate postoperative analgesia.
Preparation	The supplied lyophilized powder must be reconstituted and then diluted to a final concentration (typically 20 to 250 mug/mL) using approved diluents like Sodium Chloride 0.9%.
Delivery Method	Must be administered using a calibrated infusion device to ensure precise and consistent delivery of the dose.

---

Population and Procedural Rules

Official guidelines require dose adjustments for certain populations. For older adults (over 65 years), the initial dose for general anesthesia must be reduced by 50% compared to younger adults due to increased sensitivity. Pediatric doses (ages 1-12) are comparable to adults but require careful individual titration.

Procedurally, the infusion site must be close to the venous cannula. Due to the drug's near-immediate cessation of effect upon discontinuation, a longer-acting analgesic must be administered prior to or immediately upon stopping the Remifentanil infusion to prevent a sudden return of pain.

Research Evidence / Overview of Studies for Redormin

Evidence for Use During General Anesthesia

The body of research for Redormin (Remifentanil) is supported by Randomized Controlled Trials (RCTs), supported by subsequent meta-analyses. These studies examined the medicine's role as an analgesic and sedative adjunct during major surgical procedures. The studies included diverse groups of patients, such as adults, children (ranging from infants to adolescents), and older adults in research exploring short-term symptom changes.

Researchers focused on outcomes related to recovery speed, such as the time it took for patients to wake up and the time to safely remove the breathing tube. Studies also monitored the patient’s physiological metrics during the surgery, including blood pressure and heart rate variability.

Evidence for Symptomatic Relief in Mechanically Ventilated Patients

Research has explored the use of Redormin, typically administered as a continuous infusion, in research scenarios exploring outcomes related to physical discomfort and sedation for adults and older adults who require a breathing machine in the Intensive Care Unit (ICU). These clinical trials examined outcomes related to systemic or functional imbalance, such as the quality of pain management and depth of sedation, using specialized scoring systems.

Other study outcomes examined included the total duration patients spent on mechanical ventilation and the total length of stay in the ICU. Findings related to the duration patients required a ventilator were variable. Trials reported measurements of targeted levels of sedation and pain relief in the ICU.

What is Still Uncertain About Redormin Research

The scientific literature identifies several areas where certainty remains low or where additional research is needed. One area of ongoing discussion is the theoretical concern known as Opioid-Induced Hyperalgesia (OIH), which research is exploring. Research is ongoing to determine the clinical significance of this finding.

Evidence is limited regarding outcomes related to treatment durations exceeding 72 hours of continuous infusion. Furthermore, there is limited information available to characterize the durability of response or any impact on long-term pain patterns or general functional outcomes weeks or months after administration.

Key Studies & References Remifentanil for general anaesthesia: a systematic review (2012)

Common questions about Redormin (FAQ)

Q: Can Redormin be used by people over 65 years old?

Official product information generally indicates that this herbal combination is for use by adults. While some regulatory documents include those over 65 in the 'adult' group, specialized dosing instructions or specific recommendations for older adults are not typically specified in the consumer leaflets for this sleep aid.

Q: How does Redormin's mechanism of action differ from older sedatives?

Redormin's action involves a multi-target mechanism. Its Valerian component acts on the GABAA receptor complex to increase inhibitory signaling. Official information describes it also influences pathways regulating sleep timing, such as melatonin and serotonin signaling. This multi-target profile is described as engaging more systems than some older sedatives, which may focus primarily on one system.

Q: What defines the appropriate conditions for using Redormin?

According to official product guidelines, the medicine is indicated for the relief of sleeplessness, mild insomnia, nervous tension, and disturbed sleep. The appropriate conditions for use are typically related to these temporary sleep difficulties.

Q: Is Redormin designed to help with falling asleep, staying asleep, or both?

Studies and official information indicate that the product is designed to support both aspects of sleep. The formulation is intended to support a reduction in the time taken to fall asleep (sleep latency) and modulate the structure and duration of the sleep cycle.

Q: What is the risk of dependence or withdrawal symptoms associated with Redormin?

Some product descriptions state the herbal formula is a non-habit forming alternative. Official guidance suggests that for long periods of use, reducing the dose gradually before stopping completely is described as a strategy to minimize potential discomfort.

Q: Is Redormin a habit-forming medicine?

The herbal formula is generally described in product information as a non-habit forming option. It is intended to be used as a temporary aid and is described as having a low risk of dependence.

Q: Can I take Redormin if I am already taking supplements for anxiety?

Redormin can potentially cause increased sedation when combined with other central nervous system (CNS) depressants. Since supplements for anxiety may also have CNS depressant effects, official information advises caution when combining them.

Q: How long does it typically take for Redormin to start working?

The effects may not be immediate. Clinical studies indicate it may be necessary to take the product nightly for a period, such as 1 to 2 weeks, to experience the full support for sleep described in research.

Q: Is it normal to feel groggy or tired the next morning after taking Redormin?

Next-day effects, such as morning drowsiness or mental dullness, are listed in some official sources as possible side effects. These effects may be more noticeable in sensitive individuals.

Q: What are the most commonly reported side effects of Redormin?

Commonly reported effects can include dizziness, headache, nausea, abdominal pain, stomach upset, or vivid dreams/nightmares.

Q: Are there any known issues with drinking alcohol while using Redormin?

Official warnings state that excessive consumption of alcohol is advised against while using this product. Alcohol can increase the nervous system side effects of the product, such as dizziness and drowsiness, due to combined sedative effects.

Q: Does Redormin require a doctor's prescription?

Product information from certain jurisdictions indicates the product is typically available as a non-prescription herbal medicine or listed complementary medicine.

Q: What kind of studies support the use of Redormin?

The product's use is often referenced with clinical studies that have examined the specific combination extract (Ze 91019). These studies investigated its effects on sleep quality, duration, and latency in adults experiencing sleep disturbances.

Q: Can Redormin affect my ability to drive or operate machinery?

Official warnings state that this product may cause drowsiness or dizziness. Regulatory warnings indicate that if an individual experiences drowsiness or dizziness, the use of vehicles or operation of machinery is advised against.

Q: Is Redormin considered a controlled substance?

Regulatory classification typically describes the product as a non-controlled substance. It is commonly listed as a complementary or traditional herbal medicine in jurisdictions where it is available.

Q: Can Redormin cause dizziness or lightheadedness?

Dizziness is explicitly listed in official product information as a possible side effect of the product.

Q: Is it possible to have an allergic reaction to Redormin?

Official product information lists a known allergy to Valerian, Hops, or the product's other ingredients (excipients) as a condition where use is cautioned against. This indicates the potential for allergic reactions.

Q: Does Redormin interact with common pain relievers like ibuprofen?

Official sources describe the product interacting with medications that are changed and broken down by the liver (specifically CYP 3A4 and CYP 2D6 substrates). Whether an interaction occurs depends on if the specific pain reliever is metabolized by the CYP 3A4 or CYP 2D6 systems.

Q: What is the general duration of treatment with Redormin described in official sources?

The product is generally described for short-term use for temporary sleep issues. Clinical studies have commonly examined use for periods up to 4 to 8 weeks. In some regulatory documents, information is provided indicating that if symptoms persist, consulting a health professional is generally recommended.

Q: Are there any dietary restrictions mentioned in relation to Redormin?

Warnings are present regarding potential interactions with grapefruit or grapefruit juice. This is due to grapefruit's effect on certain liver enzymes (CYP 3A4) that are involved in the metabolism of the product's components.

Q: Is Redormin safe for long-term use, according to current research?

The product is generally recommended for short-term use. Some official sources note that the safety of continuous long-term use for this specific combination has not been definitively established in all jurisdictions.

Q: Does Redormin affect blood pressure or heart rate?

Heart disturbances or palpitations have been anecdotally reported in some sources as a possible side effect. However, these reports are not widely substantiated by clinical research.

Q: Is Redormin approved for use in children or teenagers?

Official patient information typically describes the product as not being intended for use by children or adolescents under 12 or 18 years of age. This is because its suitability for these younger age groups has not been established in the clinical data.

Q: How is Redormin described in official documents regarding its purpose?

The official purpose described in regulatory documents is to relieve sleeplessness, restless sleep, and to help restore healthy sleep patterns.

Q: What are the contraindications listed for Redormin use?

Official contraindications generally include a history of allergy to Valerian, Hops, or the other product ingredients. It is also contraindicated for use during pregnancy or breastfeeding.

Q: Is Redormin known to interact with herbal products?

Given the product's sedative nature, interactions with other sedative herbal products are considered possible due to the potential for additive central nervous system (CNS) depression.

Q: Are there different strengths or formulations of Redormin available?

The product is available in various retail formats (e.g., tablets, liquid tinctures) and sometimes offered in a Forte strength, but the core specific extract combination (Ze 91019) is consistent across these products.

Q: Is Redormin chemically similar to benzodiazepines?

The Valerian component acts as a Positive Allosteric Modulator (PAM) of the GABAA receptor complex in the brain. Benzodiazepines also target this same receptor, giving them a similar ultimate function of increasing inhibitory signaling.

Q: What is the process for discontinuing Redormin, according to official guidance?

Some official monographs describe that if the product has been used for a long period, a gradual reduction of the dose over a week or two before stopping completely is suggested. This slow reduction is described as a strategy to minimize potential discomfort.

Q: Can Redormin cause changes in appetite or weight?

Stomach upset and abdominal pain are listed as possible side effects in official sources. While these may indirectly influence appetite, no direct statement on weight change is generally available in the product information.

Q: Are there any specific warnings for individuals with liver or kidney conditions?

Rare cases of Valerian affecting the liver have led to warnings in some jurisdictions. Official warnings generally state that if signs of liver issues (e.g., yellowing skin/eyes, unusual fatigue) occur, stopping use and consulting a health professional is typically recommended.

Q: What is the recommended timing for taking Redormin?

Official product information describes the standard timing for the product's consumption as half an hour to one hour before bedtime with water.

Q: Does the efficacy of Redormin vary based on the type of sleep issue?

The efficacy described in studies focuses on relieving mild insomnia and disturbed sleep. Official sources state it is generally not deemed effective for severe or chronic insomnia requiring medical treatment.

Q: What are the limitations of the clinical research on Redormin?

Regulatory authorities generally classify Valerian-Hops as traditional or complementary medicine, noting that while clinical studies exist for the specific combination, the overall evidence for Valerian is limited.

Q: Are headaches a common side effect of Redormin?

Headaches are explicitly listed as a possible side effect of the product in official patient leaflets.

Q: Are there any known interactions between Redormin and birth control pills?

Redormin is known to interact with medicines metabolized by the CYP 3A4 and 2D6 liver enzyme systems. If birth control pills are metabolized through these pathways, a possible interaction exists.

Q: Is Redormin available under different brand names in other countries?

Yes, the specific Valerian-Hops combination extract (Ze 91019) is sold internationally under different brand names. These include ReDormin, Redormin Forte, and Ivel in various global jurisdictions.

Q: What percentage of users experience relief with Redormin in studies?

Clinical studies have reported a significant enhancement in sleep duration and quality compared to placebo. However, exact percentages of responders may vary across different trials and regulatory summaries.

Q: Does Redormin interact with grapefruit or grapefruit juice?

Warnings are present regarding potential interactions with grapefruit or grapefruit juice. This is due to grapefruit's effect on certain liver enzymes (CYP 3A4) that are involved in the metabolism of the product's components.

Q: What information is available about Redormin's safety during pregnancy?

Official product information describes avoiding use during pregnancy and breastfeeding as a general precaution. This caution is due to a lack of reliable data confirming its safety for the fetus or infant.

Q: Can Redormin be taken with other medicines that cause drowsiness?

Official guidance describes that combining the product with other sedative medications may increase the risk of excessive sedation. This is advised unless specifically instructed by a healthcare professional.

Q: Does Redormin have a risk of paradoxical reactions, such as increased excitability?

Excitability is listed in some official sources as an infrequently reported side effect of the Valerian component, which is considered a paradoxical reaction.

Q: Are there specific patient groups that should not use Redormin?

Patient groups for whom use is generally cautioned against include those with a known allergy to the ingredients, pregnant or breastfeeding individuals, and children under 12 or 18 (depending on the specific product and regional guidance).

Q: Can Redormin cause vivid or unusual dreams?

Vivid dreams or nightmares are explicitly listed in official product information as a possible side effect.

Q: Is there a link between Redormin and changes in mood or behavior?

Reports of side effects include irritability and anxiety in some sources. This suggests a possible link to changes in mood or behavior, though reports are generally infrequent.

Q: What types of drug interactions are generally described for Redormin?

General types of interaction described in regulatory sources include those with Central Nervous System (CNS) depressants (including alcohol) and medications metabolized by the CYP 3A4 and 2D6 liver enzyme systems.

Q: Do official sources describe an expected timeframe for seeing full effects?

Official product information states that the full effects of the combination are generally expected after 1 to 2 weeks of continuous nightly use. This timeframe reflects that the effects are often described as cumulative.

How to Store and Dispose of Redormin?

The storage of Redormin (Remifentanil) must follow specific regulatory requirements for both the powder and the prepared solution to maintain product stability.

Storage Condition
Unreconstituted Powder: Store at Controlled Room Temperature (20 C to 25 C).
Protection: Keep in the original carton and protected from light. Do not freeze.

Once the powder is reconstituted, the solution is stable for 24 hours at either room temperature or when refrigerated (2 C to 8 C). The medication must always be stored out of the sight and reach of children.

Disposal must strictly adhere to regulatory procedures for controlled substances. Do not throw unused or expired product into wastewater or household waste; waste must be discarded safely according to local controlled substance disposal regulations.